CIK 0001434316 · Non-accelerated filer<br>Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 651311552
- Phone
- 858.875.1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Adawi Kamal Chief Financial Officer | Sale | −6,582 | $2.05 | $14K | 93,418 |
| 2026-08-04 | TAHL CINDY See Remarks | Sale | −38,800 | $2.46 | $95K | 589,355 |
| 2026-08-04 | Valamehr Bahram President and CEO | Sale | −43,947 | $2.46 | $108K | 591,815 |
| 2026-06-12 | Xu Yuan Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | Jooss Karin Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | EPSTEIN ROBERT S Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | Agarwal Shefali Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | ABERNETHY MATT Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | RASTETTER WILLIAM H Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | Hamill Laura Director | Grant or award · Stock Option (Right to Buy) | +175,800 | 175,800 | ||
| 2026-06-12 | Redmile Group, LLC Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-06-12 | Lee Michael Stewart Director | Grant or award · Stock Option (Right to Buy) | +87,900 | 87,900 | ||
| 2026-05-20 | TAHL CINDY See Remarks | Sale | −25,590 | $1.88 | $48K | 628,155 |
| 2026-05-20 | Valamehr Bahram President and CEO | Sale | −28,946 | $1.88 | $54K | 635,762 |
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise | +122,220 | $1.32 | $161K | 609,301 |
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise | +44,444 | $1.05 | $47K | 653,745 |
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise · Stock Option (Right to Buy) | −122,220 | 152,780 | ||
| 2026-05-06 | TAHL CINDY See Remarks | Option exercise · Stock Option (Right to Buy) | −44,444 | 355,556 | ||
| 2026-05-05 | EPSTEIN ROBERT S Director | Option exercise | +25,000 | $1.69 | $42K | 36,331 |
| 2026-05-05 | EPSTEIN ROBERT S Director | Option exercise · Stock Option (Right to Buy) | +25,000 | 0 |
Page 1 of 8 · 144 trades